≥98% (HPLC)

Empirical Formula (Hill Notation):
Molecular Weight:
MDL number:
PubChem Substance ID:

Quality Level


≥98% (HPLC)




white to beige


DMSO: 20 mg/mL, clear

storage temp.


SMILES string




InChI key



5, 25 mg in glass bottle

Biochem/physiol Actions

Bromodomains (BRDs) are protein-interaction modules that "read" ε-N-lysine acetylation motifs, such as those found in the N-terminal tails of histones. BRDs have been identified in chromatin-modifying enzymes (such as histone acetyltransferases (HATs)) as well as in transcription factors that regulate genes for cell cycle progression, signal transduction, apoptosis, and inflammation. Proteins containing bromodomains have been implicated in various diseases, such as cancers, inflammatory diseases and neurological diseases. Bromosporine is a broad spectrum BRD inhibitor. In HeLa cells, bromosporine accelerates FRAP recovery of BRD4 and CREBBP at 1μM. For full characterization details, please visit the Bromosporine probe summary on the Structural Genomics Consortium (SGC) website.

To learn about other SGC chemical probes for epigenetic targets, visit

Features and Benefits

Bromosporine is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Hanyu Pan et al.
Oncotarget, 8(55), 94104-94116 (2017-12-08)
The long-lived latent HIV-1 reservoir is the major barrier for complete cure of Acquired Immune Deficiency Syndrome (AIDS). Here we report that a novel bromodomain and extraterminal domain (BET) inhibitor bromosporine which can broadly target BETs, is able to potently...
Flore Mietton et al.
Nature communications, 8, 15482-15482 (2017-05-19)
Invasive fungal infections cause significant morbidity and mortality among immunocompromised individuals, posing an urgent need for new antifungal therapeutic strategies. Here we investigate a chromatin-interacting module, the bromodomain (BD) from the BET family of proteins, as a potential antifungal target...
Berkley E Gryder et al.
Cancer discovery, 7(8), 884-899 (2017-04-28)
Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and adolescent young adults, driven primarily by the chimeric transcription factor PAX3-FOXO1. The mechanisms by which PAX3-FOXO1 dysregulates chromatin are unknown. We find PAX3-FOXO1 reprograms the
Alexander N Phillipou et al.
SLAS discovery : advancing life sciences R & D, 25(2), 163-175 (2019-12-26)
Malfunctions in the basic epigenetic mechanisms such as histone modifications, DNA methylation, and chromatin remodeling are implicated in a number of cancers and immunological and neurodegenerative conditions. Within GlaxoSmithKline (GSK) we have utilized a number of variations of the NanoBRET...
Ming Jang Chua et al.
International journal for parasitology. Drugs and drug resistance, 8(2), 189-193 (2018-04-10)
Bromodomain-containing proteins (BDPs) are involved in the regulation of eukaryotic gene expression. Compounds that bind and/or inhibit BDPs are of interest as tools to better understand epigenetic regulation, and as possible drug leads for different diseases, including malaria. In this...
Related Content
We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.